Skip to main content

Passage BIO, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

PASG$3.43-13.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.

​​​​​​​​​​​
ExhibitNumber​ ​Description​ ​ ​Form​ ​ ​ ​File No.​ ​ ​ExhibitFilingDate​ ​ ​Filed/FurnishedHerewith
​​​​​​​​​​​
​​​​​​​​​​​
2.1˄​Agreement and Plan of Merger and Reorganization among Passage Bio, Inc., Merger Sub, Inc. andRemix Therapeutics, Inc., dated as of June 24, 2026.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
4.1​Form of Contingent Value Rights Agreement​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
10.1​Form of Support Agreement by and between Passage Bio, Inc. and certain stockholders of Remix Therapeutics, Inc.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
10.2​Form of Support Agreement by and between Remix Therapeutics, Inc. and certain stockholders of Passage Bio, Inc.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
10.3​Form of Lock-Up Agreement.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
10.4​Form of Subscription Agreement among Remix Therapeutics, Inc. and the purchasers signatory thereto.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
10.5​Form of Registration Rights Agreement among Remix Therapeutics, Inc., Passage Bio, Inc. and the purchasers signatory thereto.​8-K​001-39231​June 24, 2026​​
​​​​​​​​​​​
31.1​Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
31.2​Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
32.1*​Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
32.2*​Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
101.INS​Inline XBRL Instance Document​​​​​​​X
​​​​​​​​​​​
101.SCH​Inline XBRL Taxonomy Extension Schema Document​​​​​​​X
​​​​​​​​​​​
101.CAL​Inline XBRL Taxonomy Extension Calculation Linkbase Document​​​​​​​X
​​​​​​​​​​​
101.DEF​Inline XBRL Taxonomy Extension Definition Linkbase Document​​​​​​​X
​​​​​​​​​​​
101.LAB​Inline XBRL Taxonomy Extension Label Linkbase Document​​​​​​​X
​​​​​​​​​​​
101.PRE​Inline XBRL Taxonomy Extension Presentation Linkbase Document​​​​​​​X
​​​​​​​​​​​
104​Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)​​​​​​​X

ad

​​​
​​​
*​This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.​
˄​The annexes, schedules and/or certain exhibits to this agreement have been omitted pursuant to Item 601(b)(2) or Item 601(a)(5) of Regulation S-K.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.